In terms of unique molecular features, 29% of low-grade ovarian endometrioid adenocarcinomas with concurrent endometriosis contained mutations in KRAS compared to 3% of low-grade endometrioid adenocarcinomas lacking endometriosis [33]. The gene discussed is KRAS; the disease is endometriosis.